相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4
Shidong Lv et al.
ONCOGENE (2018)
A comprehensive review of protein kinase inhibitors for cancer therapy
Radhamani Kannaiyan et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
Yanis Boumber
JOURNAL OF THORACIC DISEASE (2018)
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
Nneha Sakre et al.
ONCOTARGET (2017)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
June-Koo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions
Christian Rolfo et al.
LABORATORY INVESTIGATION (2017)
Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
You-cai Zhu et al.
ONCOTARGETS AND THERAPY (2017)
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas
Lydia Meder et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Teresa Helsten et al.
MOLECULAR CANCER THERAPEUTICS (2016)
LRP1B deletion is associated with poor outcome for glioblastoma patients
E. Tabouret et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
J. S. Ross et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
PTEN Is a Potent Suppressor of Small Cell Lung Cancer
Min Cui et al.
MOLECULAR CANCER RESEARCH (2014)
ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis
Yi Zhang et al.
TUMOR BIOLOGY (2014)
Small Cell Lung Cancer
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
Prue A. Cowin et al.
CANCER RESEARCH (2012)
Management of Small Cell Lung Cancer
Raffaele Califano et al.
DRUGS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Advances in understanding cancer genomes through second-generation sequencing
Matthew Meyerson et al.
NATURE REVIEWS GENETICS (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
APC mutations are infrequent but present in human lung cancer
H Ohgaki et al.
CANCER LETTERS (2004)
分享论文
